General
Preferred name
ANACETRAPIB
Synonyms
MK-0859 ()
Anacetrapib (MK-0859) ()
Anacetrapib/MK-0859 ()
MK0859 ()
Anacetrapib ()
P&D ID
PD013008
CAS
875446-37-0
Tags
available
drug candidate
Drug indication
Arteriosclerosis
Hyperlipidaemia
Drug Status
investigational
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Anacetrapib is an investigational compound which inhibits cholesterylester transfer protein (CETP) .
DESCRIPTION Anacetrapib is a small molecule that inhibits cholesterylester transfer protein (CETP; P11597) . CETP was considered as a target for prevention of dyslipidemia and resucing cardiovascular mortality, with CETP inhibitors proposed as a direct route to raise HDL.
Clinical trial results for a number of CETP inhibitors have failed to show clinical benefit. Failed candidates include , anacetrapib, torcetrapib, and dalcetrapib . (GtoPdb)
Compound Sets
13
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
26
Properties
(calculated by RDKit )
Molecular Weight
637.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
9.76
TPSA
38.77
Fraction CSP3
0.37
Chiral centers
2.0
Largest ring
6.0
QED
0.25
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Metabolism
Metabolic Enzyme/Protease
Target
Mutant CETP (C13S)
rhCETP
CETP
CETP,LDL
MOA
cholesteryl ester transfer protein inhibitor
Source data